We would love to hear your thoughts about our site and services, please take our survey here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
25/2/20 - ONCOLOGIE, INC. ANNOUNCES COLLABORATION WITH MOFFITT CANCER CENTER TO ADVANCE THE DEVELOPMENT OF PRECISION MEDICINE FOR THE TREATMENT OF GASTRIC AND GASTROINTESTINAL CANCERS
The two organizations expect to share findings from the collaboration at an appropriate medical meeting later this year.
there`s those 100k trades going through again,
same time every day, always bang on mid price,
I was offered 24 to sell 30k, so I`m guessing they
are buys
VERY funny today people buying today at 24/25 i hit it right the prices i paid -- KNEW it was cheap next one destiny pharma in a few months it will hot up buying now is prudent
Can sell at full ask too. They want shares
That Navicixizumab has had excellent results in tests on very advanced ovarian cancer. The median Progression Free Survival was 7.3 months. That was on cancers which had resisted three other treatments. Maybe if it was used as a first line of defence, instead of a last line of defence, the survival times would be even longer.
“ The FDA has granted Fast Track designation to navicixizumab for the treatment of high grade ovarian, primary peritoneal or fallopian tube cancer in patients who have received at least 3 prior therapies and/or prior bevacizumab. Following a Type B End of Phase 1 meeting with the FDA held in July 2019, the FDA agreed in principle on an outline for a Phase 2 clinical trial that could potentially support accelerated approval of navicixizumab in this ovarian cancer patient population.”
This is certainly a life extender, if not a life saver. Seven months or longer, is a massive gift to patients with terminal cancer,
Nice buys at full ask coming in
A buyer of 100K at 24.70p just now 9:03 am naturally paying a premium as the offer was 22p
With sells done and price settle at 21 v 22p, the buyers started to noble again.
GOOD LUCK MOST
2 chunky trades at 24.85, above ask, when sp showed 23 - 24. Could be interesting in the lead to results if the gains hold this time.
This could be exciting. Join the dots.
Oncologie, Inc - Collaborating with Moffitt Cancer Centre to develop cancer treatments. Navicixizumab licensed to Oncologie, Inc.
Moffitt Cancer Centre collaborating with Memgen.
Navicixizumab (OMP-305B83) is an anti-DLL4/VEGF bispecific antibody designed to inhibit both Delta-like ligand 4 (“DLL4”) in the Notch cancer stem cell pathway as well as vascular endothelial growth factor (“VEGF”) and thereby induce potent anti-tumor responses while mitigating certain angiogenic-related toxicities.
Memgen
Memgen is developing new therapies to harness the power of the immune system to potentially cure cancer and to protect people from COVID-19 and other diseases.
The Company's lead cancer immunotherapy, MEM-288, was developed in collaboration with Moffitt Cancer Center. It is an oncolytic virus engineered to selectively target cancer cells and to supercharge the immune system through expression of two unique and powerful immune modulators: MEM40 and the powerful cytokine interferon beta. MEM-288 generates a strong systemic anti-tumor immune response following intra-tumoral vaccination in multiple tumors. Memgen expects to begin clinical testing with MEM-288 in advanced cancers in the current year.
Memgen's COVID-19 vaccine, MemVax, is an adjuvant designed to be used in combination with other COVID-19 vaccines to generate a strong, durable immune response. MemVax is a highly specific immune stimulant that can work with COVID-19 antigens across a range of delivery approaches. Memgen has over 100,000 doses of MemVax ready to go into clinical trials and an active file with the US FDA. Memgen plans to soon begin clinical trials of MemVax in collaboration with other companies developing complementary COVID-19 vaccines.
https://www.prnewswire.com/news-releases/memgen-announces-research-to-be-presented-at-2020-american-association-of-cancer-research-aacr-meeting-301068860.html
28p would make me happy I would be even I missed last gilead influence spike to trade and buy cheaper but I am here for Long so all is good
The price here was about 26-28P the last time Nasdaq was 1.80. Would expect it open lower than that though and wait for Nasdaq to open again tomorrow to confirm the rise before it rerates to Nasdaq valuation. The Nasdaq volume was the highest since 27th December and we did see large rise at that point
It finished on 44.3% up nice I might be out from red after long time ;) fingers crossed , ps still I would like to know what moved it up
Sorry i didn't see it it is stocktwits.com
What website was that...can’t find it under the name stockists
49% now, looking strong!
I could be wrong it is going up , saying that I still can't find any news
Down to 35% now typical pump and dump
People on stockists.com saying no news , it dropped to 54% now
I don`t know about the pump, it was always going to be
one of those shares that caught people out!
Daily average trading volume is 73000 opposed to 1.2 mill currently.. looks good for a big move tomorrow.
Some of it will be pump and dump but what is the news ?
$2.13 NOW, got to be an rns soon!
80% now